FDA Restricts Cell Therapeutics Drug Trial Following Death

Law360, New York (June 24, 2013, 3:42 PM EDT) -- The U.S. Food and Drug Administration has restricted clinical studies of Cell Therapeutics Inc.’s experimental blood cancer drug tosedostat after a patient died during a trial, blocking new trial participants from enrolling until the matter is fully investigated, the drugmaker announced Monday.

According to a filing made with the U.S. Securities and Exchange Commission, the FDA notified the Seattle-based cancer drug specialist on June 17 that it had put a partial hold on clinical work underpinning CTI’s investigational new drug application for tosedostat following the patient...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.